United States Hypophosphatasia Molecular Research Center

Last updated: August 5, 2024
Sponsor: Children's Mercy Hospital Kansas City
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Whole Genome Sequencing

Clinical Study ID

NCT05062629
STUDY00001708
  • Ages 1-120
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

This study is being done to determine if cryptic alterations exist within or near to the ALPL gene in patients with a clinical diagnosis of hypophosphatasia, but without identifiable alteration on commercial testing. Additionally, the study aims to characterize functional effects of certain variants of uncertain significance in patients with clinical diagnosis of hypophosphatasia.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Aim 1-

  1. Diagnosis of Hypophosphatasia based on clinical features that include
  • History consistent with diagnosis of hypophosphatasia AND

  • Physical examination findings consistent with a diagnosis of hypophosphatasiaAND

  • Presence of low serum alkaline phosphatase level for age and sex AND

  • Elevation of at least one natural substrate of alkaline phosphatase

  1. Lack of detection of a variant on molecular analysis of the ALPL gene. Whenpossible, first degree relatives (parents, siblings, or child) will be included forthe sole purpose of trio testing. No additional information will be collected onfirst degree relatives.

Aim 2-

  1. Missense variant in ALPL which is interpreted as a variant of uncertain significanceby the American College of Medical Genetics Guidelines for Variant Interpretation

  2. Variant has been interpreted as pathogenic, likely pathogenic, likely benign, orbenign using ex-US interpretation guidelines

Exclusion

Exclusion Criteria:

Aim 1-

  1. History and physical examination incompatible with a diagnosis of hypophosphatasiaOR

  2. Absence of hypophosphatasemia as measured by age and sex-matched control OR

  3. Absence of at least one elevated natural substrate of alkaline phosphatase OR

  4. Alternate diagnosis which could overlap with signs and symptoms of hypophosphatasia

Aim 2-

  1. Inability to express variant in plasmid for residual enzyme and co-transfectionanalyses

Study Design

Total Participants: 66
Treatment Group(s): 1
Primary Treatment: Whole Genome Sequencing
Phase:
Study Start date:
August 24, 2021
Estimated Completion Date:
August 01, 2026

Study Description

Primary Study Objectives:

Determine if cryptic alterations exist within or near to the ALPL gene in patients with clinical diagnosis of hypophosphatasia, but without identifiable pathogenic or likely pathogenic variant on commercial testing.

Secondary Study Objective(s):

Characterize functional effects of variants of uncertain significance in patients with clinical diagnosis of hypophosphatasia

Further characterize the differential diagnosis of hypophosphatasemia in patients with skeletal disease

Connect with a study center

  • Children's Mercy Hospital

    Kansas City, Missouri 64108
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.